SCHEMBL3085667

SCHEMBL3085667

Fc1ccc(-c2cn3ccnc3s2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 3/20 0.38
TGFBR1 P36897 4/20 0.36
TP53 P04637 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPK14 Q16539 1/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
DYRK1A Q13627 2/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
IKBKB O14920 1/20 0.34
CHUK O15111 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
TYK2 P29597 1/20 0.34
PDPK1 O15530 1/20 0.34
DCTPP1 Q9H773 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9488964 0.83 DYRK1A (0.34) DYRK1AKDM4EALDH1A1HPGD
SCHEMBL567444 0.82 EGFR (0.47) DYRK1AKDM4EALDH1A1HPGD
SCHEMBL6668614 0.69 KDM4E (0.55) TP53SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL1830448 0.68 DYRK1A (0.71) TGFBR1DYRK1ACYP1A2
SCHEMBL13336494 0.68 NPC1 (0.51) TGFBR1TP53MAPK14NPC1RAB9A
SCHEMBL22777380 0.67 ADORA2A (0.47) TGFBR1MAPK14
SCHEMBL3085669 0.64 IDO1 (0.71) FLT3SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL30537915 0.64 KDM4E (0.41) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL18190039 0.63 NPC1 (0.57) TP53SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL23535638 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790741-B2 Imidazothiazoles and imidazoxazoles ABBOTT LABORATORIES (US) 2010-09-07 US disclosed
US-20080161341-A1 Novel imidazothiazoles and imidazoxazoles ABBVIE INC. 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161341-A1 Novel imidazothiazoles and imidazoxazoles MAP3K1, MAP3K19, MAP3K5 FLT3 273/4885TGFBR1 1209/4885TP53 679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.